- Home
- ACRE vs CDXS Comparison
ACRE vs CDXS Comparison
Compare ACRE & CDXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ACRE | CDXS |
|---|---|---|
| Founded | 2011 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Major Chemicals |
| Sector | Real Estate | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 254.1M | 256.3M |
| IPO Year | 2011 | 2008 |
Fundamental Metrics
Financial Performance| Metric | ACRE | CDXS |
|---|---|---|
| Price | $4.92 | $2.70 |
| Analyst Decision | Hold | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $5.38 | N/A |
| AVG Volume (30 Days) | 393.8K | ★ 986.0K |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | ★ 11.58% | N/A |
| EPS Growth | 26.17 | ★ 43.82 |
| EPS | ★ 1.35 | N/A |
| Revenue | $54,833,000.00 | ★ $138,590,000.00 |
| Revenue This Year | N/A | $7.73 |
| Revenue Next Year | $16.28 | $14.24 |
| P/E Ratio | $3.66 | ★ N/A |
| Revenue Growth | N/A | ★ 32.30 |
| 52 Week Low | $4.05 | $0.96 |
| 52 Week High | $5.89 | $3.87 |
Technical Indicators
Market Signals| Indicator | ACRE | CDXS |
|---|---|---|
| Relative Strength Index (RSI) | 49.01 | 57.94 |
| Support Level | $4.58 | $2.39 |
| Resistance Level | $4.93 | $2.87 |
| Average True Range (ATR) | 0.12 | 0.16 |
| MACD | 0.02 | 0.00 |
| Stochastic Oscillator | 84.52 | 78.00 |
Price Performance
Historical ComparisonAbout ACRE Ares Commercial Real Estate Corporation
Ares Commercial Real Estate Corp is a specialty finance company and a Real Estate Investment Trust providing commercial real estate loans and related investments. It operates in one segment namely originating and managing a diversified portfolio of CRE debt-related investments. The group recognizes its revenues through the interest income it receives from loans.
About CDXS Codexis Inc.
Codexis Inc is a biotechnology company engaged in providing enzyme-based technology solutions to improve pharmaceutical manufacturing processes. The company operates through two key business areas: the ECO Synthesis manufacturing platform and small molecule pharma biocatalysis. The ECO Synthesis platform focuses on developing enzymatic processes for the large-scale manufacture of RNA interference therapeutics, while the biocatalysis business utilizes engineered enzymes to enhance efficiency, yield, and sustainability in small molecule drug manufacturing. Geographically, it derives maximum revenue from the Americas.